local_hospital

Istituto Ortopedico Rizzoli

Address
lock Available on a paid plan

Musculoskeletal Diseases and Orthopedic Regeneration

At Istituto Ortopedico Rizzoli in Bologna, clinical trials in musculoskeletal diseases focus on conditions that affect bones, joints, and connective tissues, with a strong emphasis on osteogenesis imperfecta, osteosarcoma, and challenging fracture healing.

  • Testing new treatments for brittle bone disease and reducing fracture risk in osteogenesis imperfecta
  • Evaluating therapies for delayed union and non-union long bone fractures to improve bone repair
  • Studying treatment approaches for osteosarcoma and other high-risk bone sarcomas

This research area aims to improve healing, strengthen bone outcomes, and support better long-term function for patients with complex orthopedic conditions.

Sarcoma and Rare Bone Cancer Research

A major part of the site’s work is dedicated to neoplasms, especially rare and aggressive cancers such as leiomyosarcoma, chondrosarcoma, Ewing sarcoma, and soft tissue sarcoma.

  • Assessing new anticancer therapies for advanced or metastatic sarcomas
  • Comparing treatment strategies to improve survival and disease control in leiomyosarcoma
  • Studying options for refractory or recurrent Ewing sarcoma and other difficult-to-treat sarcomas

The goal is to find more effective and better-tolerated treatments for patients with rare cancers that often have limited standard options.

Targeted and Immune-Based Oncology Studies

The Research, Innovation and Technology Department also supports trials exploring targeted and immune-based approaches for advanced cancers, including tenosynovial giant cell tumor, desmoid tumors, and selected sarcoma subtypes.

  • Testing targeted therapies designed to slow or stop tumor growth
  • Evaluating immune-focused treatments for advanced solid tumors
  • Measuring whether new combinations can improve tumor response and progression control

These studies are aimed at expanding treatment choices and improving outcomes for patients with hard-to-treat tumors.

Inflammatory and Immune System Conditions

The site also conducts research in immune system diseases, with attention to non-radiographic axial spondyloarthritis and related inflammatory conditions that can cause pain, stiffness, and reduced mobility.

  • Evaluating medicines that help maintain remission and prevent disease flare-ups
  • Studying how well treatments control inflammation over time
  • Supporting better symptom management and quality of life in chronic immune-mediated disease

This work seeks to improve long-term disease control while reducing the burden of persistent inflammation for patients.

Advanced Orthopedic and Connective Tissue Innovation

Research at Istituto Ortopedico Rizzoli also extends to skin and connective tissue diseases and advanced orthopedic innovation, reflecting the center’s interest in tissue repair, structural recovery, and supportive care.

  • Exploring therapies that may improve connective tissue healing and recovery
  • Assessing treatment effectiveness in complex orthopedic and tumor-related conditions
  • Investigating ways to improve diagnostics, response assessment, and patient outcomes

This broad research activity connects laboratory insight with clinical care, helping advance treatment for patients with rare and difficult musculoskeletal disorders.

Site Overview

assignment
25
connected trials
corporate_fare
21
sponsors
science
48
IMPs

Activity Indicator

Last 6 months

1
Trials started
-50% vs previous period.
2
Trials started 6–12 months ago
25
Total trials linked
Highly Active
trending_downDeclining-50%
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 4 of 5 therapeutic areas and 15 of 48 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 48 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
11
Sponsors (total)
21
Active sponsors
9

Sponsor Network

Top 9 by active trials.

lock +8 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +3 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 566 other sites in Italy

description
Trial volume
25
Outperforms 77% of sites
public
Therapeutic diversity
5areas
Outperforms 71% of sites
groups
Sponsor diversity
21sponsors
Outperforms 78% of sites

Therapeutic Area Benchmark — Italy

Select a therapeutic area to compare against other sites in Italy.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Italy

Market Share

Country: Italy

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Istituto Ortopedico Rizzoli

lock Showing 1 of 25 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Phase 3 Multicenter Randomized Study Comparing INT230-6 (Vinblastine Sulfate, Cisplatin) to Standard Care in Adults with Metastatic Soft Tissue SarcomasIntensity Therapeutics Inc.Phase IIINot Yet RecruitingNov 2024

IMP list

lock Showing 1 of 48 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Doxorubicin Hydrochloride3Unknown2017-10-092025-12-19

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.